FREE Biopharma Daily Stock Updates - 02/17/21

Want to access our searchable database of catalysts and companies? Get access to BiopharmIQ for 30 days free, no credit card required. Check it out here!

$XBI $160.72 +1% 📈


Covid Updates

$RDHL +4% First patient dosed in ph 2/3 study of RHB-107. source


Pipeline Updates


$NKTR +13% Collaboration with SFJ Pharma for up to $150M to support registrational phase 2/3 trial of BEMPEG + KEYTRUDA in patients with head and neck cancer whose tumors express PD-L1. source


$VTVT +7% Phase 1 initiation of HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis. source


$MYOV +4% Phase 3 LIBERTY study of Relugolix published in NEJM. source


$BPMC +8% sNDA accepted accepted for AYVAKIT for advanced systemic mastocytosis (SM). The FDA granted priority review and set a PDUFA target action date of June 16, 2021. source


Financial Updates


$MTEM -1% Offering


$YMAB -9% Offering


0 comments

*Disclaimer: Information provided on bpiq.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Big Movers™ is a trademark of Amp Biotech Research, LLC

©2021 by Biopharm IQ. Website by Awaken Studio.

SITE